Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Four-arm Trial Comparing Artemether-lumefantrine With or Without Single-dose Primaquine and Sulphadoxine-pyrimethamine/Amodiaquine With or Without Single-dose Tafenoquine to Reduce P. Falciparum Transmission in Mali

Next Previous
Trial Profile

A Four-arm Trial Comparing Artemether-lumefantrine With or Without Single-dose Primaquine and Sulphadoxine-pyrimethamine/Amodiaquine With or Without Single-dose Tafenoquine to Reduce P. Falciparum Transmission in Mali

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amodiaquine (Primary) ; Artemether/lumefantrine (Primary) ; Primaquine (Primary) ; Pyrimethamine/sulfadoxine (Primary) ; Tafenoquine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Acronyms NECTAR3

Most Recent Events

  • 14 Jan 2022 Status changed from recruiting to completed.
  • 26 Nov 2021 Status changed from not yet recruiting to recruiting.
  • 20 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top